JP2009023954A - 前立腺特異抗原レベルの低下剤 - Google Patents
前立腺特異抗原レベルの低下剤 Download PDFInfo
- Publication number
- JP2009023954A JP2009023954A JP2007189114A JP2007189114A JP2009023954A JP 2009023954 A JP2009023954 A JP 2009023954A JP 2007189114 A JP2007189114 A JP 2007189114A JP 2007189114 A JP2007189114 A JP 2007189114A JP 2009023954 A JP2009023954 A JP 2009023954A
- Authority
- JP
- Japan
- Prior art keywords
- psa
- prostate
- reducing agent
- specific antigen
- level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010072866 Prostate-Specific Antigen Proteins 0.000 title claims abstract description 49
- 102000007066 Prostate-Specific Antigen Human genes 0.000 title claims abstract 5
- 239000003638 chemical reducing agent Substances 0.000 title abstract description 9
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 22
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 abstract description 9
- 229930153442 Curcuminoid Natural products 0.000 abstract description 3
- 102100038358 Prostate-specific antigen Human genes 0.000 description 44
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 14
- 206010060862 Prostate cancer Diseases 0.000 description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 235000012754 curcumin Nutrition 0.000 description 7
- 229940109262 curcumin Drugs 0.000 description 7
- 239000004148 curcumin Substances 0.000 description 7
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 241000234299 Zingiberaceae Species 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 235000021374 legumes Nutrition 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 235000010575 Pueraria lobata Nutrition 0.000 description 2
- 244000046146 Pueraria lobata Species 0.000 description 2
- 241000234314 Zingiber Species 0.000 description 2
- 235000006886 Zingiber officinale Nutrition 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000020241 curcumin extract Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 2
- 235000008397 ginger Nutrition 0.000 description 2
- OZBAVEKZGSOMOJ-MIUGBVLSSA-N glycitin Chemical compound COC1=CC(C(C(C=2C=CC(O)=CC=2)=CO2)=O)=C2C=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OZBAVEKZGSOMOJ-MIUGBVLSSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940069755 soybean germ extract Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 description 1
- 102000001779 3-oxo-5-alpha-steroid 4-dehydrogenase Human genes 0.000 description 1
- 108010029908 3-oxo-5-alpha-steroid 4-dehydrogenase Proteins 0.000 description 1
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- XJTZHGNBKZYODI-UHFFFAOYSA-N Glycitin Natural products OCC1OC(Oc2ccc3OC=C(C(=O)c3c2CO)c4ccc(O)cc4)C(O)C(O)C1O XJTZHGNBKZYODI-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 description 1
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 description 1
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 108010071652 human kallikrein-related peptidase 3 Proteins 0.000 description 1
- 102000007579 human kallikrein-related peptidase 3 Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- -1 troches Substances 0.000 description 1
- 229940052016 turmeric extract Drugs 0.000 description 1
- 235000020240 turmeric extract Nutrition 0.000 description 1
- 239000008513 turmeric extract Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
【解決手段】 クルクミノイドとイソフラボンを組み合わせてなることを特徴とする。
【選択図】 図1
Description
血中のPSAレベルが高値(10以上)であるが生検を行っても前立腺癌が見つからない対象者に、インフォームドコンセントを得て、クルクミンエキス末(ニチモウ株式会社)と発酵大豆胚芽抽出物(Medi Herb Inc.)を主な成分とする錠剤(S錠:1錠250mgあたりクルクミン52.25mgとイソフラボン(アグリコン)20mgを含有)またはプラセボ錠(P錠)を二重盲検法により割り付けた。対象者にはいずれかの錠剤を6ヶ月間連日服用してもらい(朝夕食後に各1錠ずつ)、6ヵ月後にPSAレベルを測定した。その結果、P錠を服用してもらった群ではPSAレベルは2.62しか低下しなかったのに対し(10人の平均値)、S錠を服用してもらった群ではPSAレベルが9.07低下した(15人の平均値)。よって、クルクミノイドとイソフラボンを組み合わせて投与すると、PSAレベルを効果的に低下させることができることがわかった。
ヒト前立腺癌由来細胞であるLNCaP細胞のPSA分泌量に対するクルクミノイドとイソフラボンの作用を次のようにして調べた。即ち、前出のクルクミンエキス末と発酵大豆胚芽抽出物を、それぞれ添加しないか、クルクミンとイソフラボンがそれぞれ所定の濃度となるように添加した培養液(RPMI1640:株式会社免疫生物研究所)で、LNCaP細胞を24時間培養した後(培養条件は標準的なものに準拠)、LNCaP細胞から分泌された培養液中のPSAの濃度を免疫測定した(免疫測定はR&D systems Inc.のHuman KLK3/PSA Immunoassayを使用して実施)。結果を図1に示す。図1から明らかなように、LNCaP細胞にクルクミンとイソフラボンをそれぞれ単独で添加した場合でも、LNCaP細胞のPSA分泌を抑制することはできるが、その効果は十分でなかった。これに対し、LNCaP細胞にクルクミンとイソフラボンを組み合わせて添加した場合、驚くべきことに相乗的効果が現れ、LNCaP細胞のPSA分泌をほぼ完全に抑制することができた。
クルクミン5g、イソフラボン5g、乳糖75g、ステアリン酸マグネシウム15g、合計100gを均一に混合し、常法に従って錠剤を製造した。
薄力粉32g、全卵15g、バター15g、砂糖20g、水10g、ベーキングパウダー2g、クルクミン3g、イソフラボン3g、合計100gを用い、常法に従ってビスケットを製造した。
Claims (1)
- クルクミノイドとイソフラボンを組み合わせてなることを特徴とする前立腺特異抗原レベルの低下剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007189114A JP5252848B2 (ja) | 2007-07-20 | 2007-07-20 | 前立腺特異抗原レベルの低下剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007189114A JP5252848B2 (ja) | 2007-07-20 | 2007-07-20 | 前立腺特異抗原レベルの低下剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009023954A true JP2009023954A (ja) | 2009-02-05 |
JP5252848B2 JP5252848B2 (ja) | 2013-07-31 |
Family
ID=40396111
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007189114A Active JP5252848B2 (ja) | 2007-07-20 | 2007-07-20 | 前立腺特異抗原レベルの低下剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5252848B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019187039A1 (ja) | 2018-03-30 | 2019-10-03 | 三菱ケミカルエンジニアリング株式会社 | 微細気泡発生用ノズル、該微細気泡発生用ノズルを用いて液体に微細気泡を含む気泡を混合させる方法、該微細気泡発生用ノズルを備えた生物反応装置、および該微細気泡発生用ノズルを複数本備えた微細気泡発生用ノズル装置 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255568A (ja) * | 1996-03-22 | 1997-09-30 | Maruzen Pharmaceut Co Ltd | テストステロン−5α−レダクターゼ阻害剤、前立腺肥大症予防・治療薬および飲食物 |
JP2004196720A (ja) * | 2002-12-19 | 2004-07-15 | Nichimo Co Ltd | 前立腺疾患の予防および治療製剤 |
WO2007035766A2 (en) * | 2005-09-19 | 2007-03-29 | The Johns Hopkins University | Biomarker for prostate cancer |
-
2007
- 2007-07-20 JP JP2007189114A patent/JP5252848B2/ja active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09255568A (ja) * | 1996-03-22 | 1997-09-30 | Maruzen Pharmaceut Co Ltd | テストステロン−5α−レダクターゼ阻害剤、前立腺肥大症予防・治療薬および飲食物 |
JP2004196720A (ja) * | 2002-12-19 | 2004-07-15 | Nichimo Co Ltd | 前立腺疾患の予防および治療製剤 |
WO2007035766A2 (en) * | 2005-09-19 | 2007-03-29 | The Johns Hopkins University | Biomarker for prostate cancer |
JP2009509169A (ja) * | 2005-09-19 | 2009-03-05 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺癌のためのバイオマーカー |
Also Published As
Publication number | Publication date |
---|---|
JP5252848B2 (ja) | 2013-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Potential mechanisms of action of dietary phytochemicals for cancer prevention by targeting cellular signaling transduction pathways | |
Chen et al. | Flavone inhibition of tumor growth via apoptosis in vitro and in vivo | |
Kasimsetty et al. | Colon cancer chemopreventive activities of pomegranate ellagitannins and urolithins | |
Juan et al. | Colorectal cancer chemoprevention by trans-resveratrol | |
Canene-Adams et al. | Combinations of tomato and broccoli enhance antitumor activity in dunning r3327-h prostate adenocarcinomas | |
Landete | Plant and mammalian lignans: A review of source, intake, metabolism, intestinal bacteria and health | |
Yodkeeree et al. | Curcumin, demethoxycurcumin and bisdemethoxycurcumin differentially inhibit cancer cell invasion through the down-regulation of MMPs and uPA | |
US8034388B2 (en) | Anthocyanin-rich compositions and methods for inhibiting cancer cell growth | |
US8323706B2 (en) | Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis | |
Ionescu et al. | Dietary phytoestrogens and their metabolites as epigenetic modulators with impact on human health | |
WO2016173435A1 (zh) | 吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物 | |
Pejčić et al. | The polyphenols as potential agents in prevention and therapy of prostate diseases | |
Jo et al. | Fisetin attenuates cerulein-induced acute pancreatitis through down regulation of JNK and NF-κB signaling pathways | |
CN105482129A (zh) | 抗癌萃取物及化合物 | |
Guo et al. | S-petasin induces apoptosis and inhibits cell migration through activation of p53 pathway signaling in melanoma B16F10 cells and A375 cells | |
Wei et al. | Pomegranate peel extract ameliorates liver fibrosis induced by carbon tetrachloride in rats through suppressing p38MAPK/Nrf2 pathway | |
Vennila et al. | Modifying effects of morin on the development of aberrant crypt foci and bacterial enzymes in experimental colon cancer | |
Sain et al. | Potential of olive oil and its phenolic compounds as therapeutic intervention against colorectal cancer: a comprehensive review | |
Schanknecht et al. | Phytochemical constituents and derivatives of Cannabis sativa; bridging the gap in melanoma treatment | |
El-Shafey et al. | The ameliorative impacts of wheat germ oil against ethanol-induced gastric ulcers: Involvement of anti-inflammatory, antiapoptotic, and antioxidant activities | |
Arber | Do NSAIDs prevent colorectal cancer? | |
JP5252848B2 (ja) | 前立腺特異抗原レベルの低下剤 | |
Wijnands et al. | Do aberrant crypt foci have predictive value for the occurrence of colorectal tumours? Potential of gene expression profiling in tumours | |
Islam et al. | Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed? | |
Croley et al. | Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100419 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121001 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130402 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130416 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5252848 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160426 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |